An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation

Katherine W Turk,Mark D Knobel,Alexandra Nothern,Garrett Friedman,Hannah Noah,Brendan Campbell,Diana C Anderson,Andreas Charidimou,Andrew Mills,Vanessa Coronel,Nacha Pierre,Beverly V Reynolds,Caroline Wagner,Leanne M Varga,John Roefaro,Laura Triantafylidis,Andrew E Budson

DOI: https://doi.org/10.1212/CPJ.0000000000200346

Abstract:Background: Lecanemab and other new amyloid-targeting immunotherapies for Alzheimer disease show notable promise but may also pose significant risk for patients. Recent findings: To facilitate the implementation and monitoring of lecanemab infusions at our tertiary medical center, we convened an interprofessional team. The team created a number of resources including patient handouts and medical documentation templates as well as systems and processes that are likely to be useful to other clinical care settings and centers. Implications for practice: It is our intent to widely share the resources and processes developed.